BUSINESS

Overseas Sales Ratio of 25 Japan Drug Makers Reaches 67% in FY2023: Tally

By Kohei Hori, Hayate Horiguchi, and Sakura Kono June 6, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The total overseas sales ratio of 25 Japanese pharma companies stood at 67.9%, topping two-thirds of their combined sales in FY2023, according to a Jiho tally. In return, the ratio of their domestic sales fell below one-third. Jiho’s biannual earnings…

To read the full story

Total Sales of 26 Japan Drug Makers Up 6.1% in H1; Shionogi Nets Largest Growth
December 12, 2023

BUSINESS

Gilead Japan Files Trodelvy for 1st-Line TNBC in PD-1/PD-L1-Ineligible Patients
February 16, 2026
FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…